Effect of clinical first-line Antiviral Agents on outcome of chronic hepatitis B treatment / 中华肝脏病杂志

ABSTRACT

Chronic hepatitis B is a progressive disease that can develop into cirrhosis, liver cancer or even liver failure if it is not treated in time. Antiviral therapy is an important means to delay the progression of chronic hepatitis B disease, through long-term inhibition of HBV DNA replication can reduce liver cell inflammation and necrosis, fibrosis, delaying and reducing liver failure, cirrhosis, HCC and other complications, which can improve the life quality and prolong survival time. Based on the data of hepatitis B first-line Antiviral Agents such as entecavir and tenofovir And so on. being used worldwide, this paper expounds the influence of antiviral therapy on the outcome of chronic hepatitis B treatment.